Atorvastatin及Pioglitazone預防高脂飲食誘發小鼠高血糖及高血脂之影響

The effect of atorvastatin and pioglitazone in the prevention of high fat diet induced hyperglycemia and hyperlipidemia in mice

黃敬詠

Atorvastatin ； Pioglitazone ； 高血糖 ； 高血脂 ； Atorvastatin ； Pioglitazone ； Hyperglycemia ； Hyperlipidemia

中山醫學大學營養學系碩士班學位論文

2017年

碩士

劉德中

繁體中文

本研究以動物模式探討，給予高飽和脂肪飲食小鼠補充低劑量之降血脂藥物Atorvastatin及低劑量之降血糖藥物Pioglitazone，對血糖及血脂升高是否有預防效果。本實驗使用由國家實驗動物中心購入之5週齡大C57BL/6JNarl小鼠，隨機分成5組：1. Normal組，為攝食正常飼料組；2. Control組，為攝食高飽和脂肪酸飼料組；3. A組，為攝食高飽和脂肪酸飼料，並添加低劑量降血脂藥物Atorvastatin組；4. P組，為為攝食高飽和脂肪酸飼料，並添加低劑量降血糖藥物Pioglitazone組；5. A+P組，為攝食高飽和脂肪酸飼料，並混合添加低劑量Atorvastatin及Pioglitazone組。實驗進行8週後犧牲，並分析小鼠心跳血壓、血糖、胰島素、血清尿酸、血液尿素氮、血清及肝臟三酸甘油脂、血清及肝臟總膽固醇、血清肌酸酐、肝臟丙二醛、肝臟丙胺酸轉胺酶、肝臟麩胺酸轉胺酶、肝臟麩胱甘太過氧化酶、肝臟脂肪酸合成酶。分析結果發現，餵食高飽和脂肪酸飲食，並補充Atorvastatin及Pioglitazone，能顯著降低小鼠血壓及胰島素濃度，並使血液尿素氮濃度下降，亦能降低小鼠血中三酸甘油脂及總膽固醇濃度，且補充低劑量之Atorvastatin更能降低小鼠血糖濃度，然而在抗氧化能力方面並沒有提升的效果。但整體而言，補充低劑量Atorvastatin及Pioglitazone對預防高飽和脂肪酸飲食所誘發之血糖及血脂上升是有其功效。

The major aim of present study was to examine the protective effect of Atorvastatin and Pioglitazone on hyperglycemia and hyperlipidemia in mice fed the diet rich in saturated fatty acids. C57BL/6JNarl mice were divided into five group: 1. Normal group (fed normal diet); 2. Control group (fed the diet rich in saturated fatty acids); 3. A group (fed the diet rich in saturated fatty acids with low dose Atorvastatin); 4. P group (fed the diet rich in saturated fatty acids with low dose Pioglitazone); 5. A+P group (fed the diet rich in saturated fatty acids with low dose Atorvastatin and Pioglitazone) for eight weeks. The levels of heart rate, blood pressure, glucose, insulin, uric acid, blood urea nitrogen (BUN), serum and liver triglycerides, serum and liver total cholesterol, malondialdehyde (MDA), alanine aminotransferase specific activity, aspartate aminotransferase specific activity, glutathione peroxidase specific activity and fatty acid synthase specific activity were measured. The results showed that the intake of low dose Atorvastatin and low dose Pioglitazone reduced blood pressure, insulin, blood urea nitrogen, serum triglycerides and total cholesterol levels. The intake of low dose Atorvastatin reduced blood glucose level. However, both of Atorvastatin and Pioglitazone cannot increase antioxidant capacity. These data suggest that Atorvastatin and Pioglitazone are potent agents for improving hyperglycemia and hyperlipidemia.

1. 1. USDA Food Composition Databases, 2016.
   連結：
2. 3. 潘文涵、吳幸娟、葉志嶸、莊紹源、張新儀、葉乃華、謝耀德。台灣人飲食與健康之趨勢：1993-1996與2005-2008兩次營養健康調查之比較。2005-2008台灣營養健康調查。
   連結：
3. 4. Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol, 2009; 103(10):1364-7.
   連結：
4. 5. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res, 2003; 37(5):471-80.
   連結：
5. 6. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the Seven Countries Study. JAMA, 1995; 274(2):131-6.
   連結：
6. 7. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP. Visceral obesity and the heart. Int J Biochem Cell Biol, 2008; 40(5):821-36.
   連結：
7. 9. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol, 2008; 45:1-16.
   連結：
8. 11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999; 340(2):115-26.
   連結：
9. 15. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Elsevier, 2004; 25(6):331-6.
   連結：
10. 16. Hardie DG. The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 2003; 144: 5179-83.
    連結：
11. 17. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem, 2003; 278(36):34268-76.
    連結：
12. 18. Samuelson G, Bratteby LE, Mohsen R, Vessby B. Dietary fat intake in healthy adolescents: inverse relationships between the estimated intake of saturated fatty acids and serum cholesterol. Br J Nutr, 2001; 85(3):333-41.
    連結：
13. 19. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr, 1965; 17:281-95.
    連結：
14. 20. Müller H, Lindman AS, Brantsaeter AL, Pedersen JI. The serum LDL/HDL cholesterol ratio is influenced more favorably by exchanging saturated with unsaturated fat than by reducing saturated fat in the diet of women. J Nutr, 2003; 133(1):78-83.
    連結：
15. 21. Lundman P, Boquist S, Samnegård A, Bennermo M, Held C, Ericsson CG, Silveira A, Hamsten A, Tornvall P. A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr Metab Cardiovasc Dis, 2007; 17(3):195-202.
    連結：
16. 22. Kuhlow D, Zarse K, Voigt A, Schulz TJ, Petzke KJ, Schomburg L, Pfeiffer AF, Ristow M. Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice. Eur J Nutr, 2010; 49(7):417-27.
    連結：
17. 23. Vykoukal D, Davies MG. Vascular biology of metabolic syndrome. J Vasc Surg, 2011; 54(3):819-31.
    連結：
18. 24. Morris MJ. Cardiovascular and metabolic effects of obesity. Clin Exp Pharmacol Physiol, 2008; 35(4):416-9.
    連結：
19. 25. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetss, 2006; 55(8):2392-7.
    連結：
20. 26. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest, 2000; 106(2):171-6.
    連結：
21. 27. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition, 1997; 13(1):65.
    連結：
22. 28. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr, 1993; 57(5S):715S-24S.
    連結：
23. 29. Joel T. Vander Lugt, José Gómez-Márquez, Joel Caldon, Larry L. Louters. Combined effects of troglitazone and muscle contraction. Biochimie, 2001; 83:445-451.
    連結：
24. 30. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism, 2005; 54(1):24-32.
    連結：
25. 31. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract, 2003; 9(5):406-16.
    連結：
26. 32. Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol, 2014; 113(10):1593-8.
    連結：
27. 33. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord, 2002; 26(S2):S28-38.
    連結：
28. 34. Stafford M, Cummins S, Ellaway A, Sacker A, Wiggins RD, Macintyre S. Pathways to obesity: identifying local, modifiable determinants of physical activity and diet. Soc Sci Med, 2007; 65(9):1882-97.
    連結：
29. 35. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr, 2012; 4:12.
    連結：
30. 36. Hoffler U, Hobbie K, Wilson R, Bai R, Rahman A, Malarkey D, Travlos G, Ghanayem BI. Diet-induced obesity in mice is associated with hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6J mice. Endocrine, 2009; 36(2):311-25.
    連結：
31. 39. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest, 1993; 91(6):2546-51.
    連結：
32. 40. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002; 123(4):1367-84.
    連結：
33. 41. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006; 8(1):48-54.
    連結：
34. 2. 歷年糖尿病盛行率。衛生福利部國民健康署，2014。
35. 8. 104年死因統計結果分析。衛生福利部國民健康署，2016。
36. 10. Haag M, Dippenaar NG. Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection. Med Sci Monit, 2005; 11(12):RA359-67.
37. 12. Pfizer pharmaceuticals LLC Lipitor Film-Coated Tablets. USPI 201503-2.
38. 13. HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase. NCBI Reference Sequence Database, 2008.
39. 14. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl, 2001; 121:13-8.
40. 37. Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol, 1999; 12(1):33-40.
41. 38. Domagała B, Hartwich J, Szczeklik A. Incides of lipid peroxidation in patients with hypercholesterolemia and hypertriglyceridemia. Wien Klin Wochenschr, 1989; 101(12):425-8.